11.14.14
Catalent, Inc. has acquired Micron Technologies, a global provider of particle size engineering technologies, expanding its drug delivery and development services and allowing the company to partner with pharma companies at the earliest stages of the drug development process. Micron’s portfolio of particle size reduction, micronization and milling technologies are used to help overcome bioavailability , stability and manufacturability challenges. Micron operates two facilities in Malvern, PA, and in Dartford, UK, and employs approximately 100 people across both sites.
Catalent’s services now range from OptiForm API optimization and Micron Technologies particle size optimization, to formulation and final dose form design through to bioavailability, such as RP Scherer Softgel lipid systems and OptiMelt hot melt extrusion technologies. Catalent can support customers through scale up, clinical and commercial manufacturing of finished oral and inhaled dose forms, including for highly potent compounds.
“This strategic acquisition allows Catalent to provide an unprecedented set of integrated development solutions and superior drug delivery technologies to the industry, partnering with our customers’ R&D teams earlier in the development cycle and helping them deliver better treatments to clinic and to market faster and more efficiently,” said John Chiminski, Catalent president and chief executive officer. “We are pleased to add Micron Technologies’ leading technologies and manufacturing expertise and welcome their highly talented management, scientific and operations teams to Catalent.”
Joseph Drost, chief executive officer of Micron Technologies, who will continue to lead this business, said, “We are excited to become part of Catalent, as there is a natural synergy between our organizations, with the global leader in advanced delivery technologies and development solutions now joining forces with a leading provider of particle size engineering technologies and integrated analytical services. Through access to Catalent’s global network, development expertise and innovative technologies, we can jointly provide end-to-end solutions to accelerate drug development programs and bring better treatments to patients worldwide.”
This is Catalent’s second acquisition since its IPO in July, and follows the acquisition of Redwood Bioscience in October 2014.
Catalent’s services now range from OptiForm API optimization and Micron Technologies particle size optimization, to formulation and final dose form design through to bioavailability, such as RP Scherer Softgel lipid systems and OptiMelt hot melt extrusion technologies. Catalent can support customers through scale up, clinical and commercial manufacturing of finished oral and inhaled dose forms, including for highly potent compounds.
“This strategic acquisition allows Catalent to provide an unprecedented set of integrated development solutions and superior drug delivery technologies to the industry, partnering with our customers’ R&D teams earlier in the development cycle and helping them deliver better treatments to clinic and to market faster and more efficiently,” said John Chiminski, Catalent president and chief executive officer. “We are pleased to add Micron Technologies’ leading technologies and manufacturing expertise and welcome their highly talented management, scientific and operations teams to Catalent.”
Joseph Drost, chief executive officer of Micron Technologies, who will continue to lead this business, said, “We are excited to become part of Catalent, as there is a natural synergy between our organizations, with the global leader in advanced delivery technologies and development solutions now joining forces with a leading provider of particle size engineering technologies and integrated analytical services. Through access to Catalent’s global network, development expertise and innovative technologies, we can jointly provide end-to-end solutions to accelerate drug development programs and bring better treatments to patients worldwide.”
This is Catalent’s second acquisition since its IPO in July, and follows the acquisition of Redwood Bioscience in October 2014.
